The Vision business at Johnson & Johnson MedTech has hit its latest milestone, earning a significant regulatory nod for its ...

Patients who received the Tecnis PureSee extended depth of focus IOL had a high tolerance to residual refractive error, ...

Uncorrected acuity at 36 months showed continuous range: monocular 20/20 distance and intermediate, 20/27 near; binocular ...

97% of patients who received the BIM-IOL System off all topical IOP-lowering therapy at 12-months 100% of BIM-IOL System patients achieved 20/32 or better BCDVA and a mean BCDVA equivalent to 20/20 ...

First-in-Human(FIH)Trialat36Months: PhaseI/IITrialat3Months: 37% and 36% reduction in mean IOP with 98% and 96% of patients off topical IOP-lowering drops in 78 mcg and 39 mcg dose groups, ...

FDA has approved Johnson & Johnson's Tecnis PureSee IOL, an extended depth of focus (EDOF) intraocular lens (IOL) intended for use in cataract surgery. The new IOL will be available to U.S. patients ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In a phase 1/2 trial, the IOL system lowered IOP at two ...

Johnson & Johnson (J&J) has received approval from the US Food and Drug Administration (FDA) for its TECNIS PureSee extended depth of focus (EDOF) intraocular lens (IOL), designed for use in cataract ...

Alcon, the global leader in eye care dedicated to helping people see brilliantly, today proudly announced that more than 175 million of its intraocular lenses (IOLs) have been implanted worldwide.9,+ ...

On March 9, 2026, SpyGlass Pharma announced positive 12-month results from its phase 1/2 trial of the Bimatoprost Drug ...